Boston Scientific is grappling with investor dissatisfaction following a net income miss and disappointing guidance for the first half of fiscal 2026, leading to a 20-40% decline in its stock. Compounding these challenges, the company is under investigation due to a class action lawsuit alleging misleading statements regarding growth. Despite these issues, Boston Scientific is pursuing aggressive expansion through a $14.5 billion acquisition of Penumbra to enhance its foothold in the mechanical thrombectomy market. As the company prepares for its earnings report on April 22, 2026, its future remains in question.
“The Passport Program is competitively selective (~60-64 advanced 4th-year GI endoscopy fellows per cohort), with registration routed through Boston Scientific territory managers based on fellowship performance and interest. It's designed as targeted hands-on training on their specific devices (ERCP, EUS, resection), with company-covered travel/lodging. So yes—it's both an honor for those chosen *and* a deliberate sponsor-led initiative to build skills, familiarity, and long-term relationships with future users.”
“The Boston Scientific Passport Program is an industry-sponsored training initiative run by Boston Scientific through their EDUCARE platform. It's targeted at 4th-year advanced endoscopy GI fellows and includes hands-on courses, eLearning, and coaching on their specific devices/procedures (e.g., ERCP, cholangioscopy, EUS, tissue resection).”
“It's not a neutral, independently accredited CME course—it's company-led product-focused education.”
“The Boston Scientific Passport Program offers targeted, hands-on training on their devices for advanced endoscopy fellows. It covers travel/lodging for select participants and focuses on product-specific skills like ERCP and EUS—not accredited, independent CME.”
“Many doctors value it for building procedural expertise that can benefit patients. Others see it as creating potential conflicts via industry ties.”
“only ~3 months into the year in healthcare services, you've seen big short alpha opportunities in relatively stable businesses like IQV, BDX, HUM, BSX, AVTR, and QDEL, all which have seen 20-40% downside moves.”
“Parnassus Value Equity Fund (Trades, Portfolio) added a total of two stocks, among them: ... the second largest addition to the portfolio was Boston Scientific Corp (NYSE:BSX), consisting of 678,208 shares, representing approximately 0.93% of the portfolio, with a total value of $42.56 million.”
“On March 30, Boston Scientific received FDA 510(k) clearance for its Asurys Fluid Management System, a new technology designed to manage irrigation and distention during endoscopic urologic procedures.”
“Boston Scientific Corporation (NYSE:BSX) is one of the 10 Best Growth Stocks to Buy for the Next Decade.”
“The Complaint alleges that, throughout the relevant period, Defendants made materially false and misleading statements and/or failed to disclose that: ... (1) Boston Scientific’s projected growth rate for fiscal year 2025... was not sustainable; ... (5) as a result of the foregoing, Defendants’ positive statements regarding the sustainability of growth in key product segments... were materially false and misleading.”
“Mechanical thrombectomy, a procedure to remove clots from blood vessels, is attracting major investments from companies such as Boston Scientific, which announced a $14.5 billion deal to acquire Penumbra in January.”
“According to the lawsuit, during the Class Period, defendants made positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Boston Scientific’s U.S. Electrophysiology segment; notably, that management was aware that the segment’s growth rate was unsustainable and that it was approaching an earlier tipping point than the market was anticipating.”